We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Agronomics Limited | LSE:ANIC | London | Ordinary Share | IM00B6QH1J21 | ORD 0.0001P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 5.65 | 5.60 | 5.70 | 5.65 | 5.59 | 5.65 | 57,298 | 08:00:24 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Investors, Nec | 30.88M | 22.37M | 0.0222 | 2.55 | 57.03M |
From Aug 2019 to Aug 2024
TIDMPEBI
RNS Number : 5168D
Port Erin Biopharma Investments Ltd
31 March 2014
Port Erin Biopharma Investments Limited
("Port Erin" or the "Company")
Interim Results for the six month period ending 31 December 2013
The Board of Port Erin, the AIM quoted company focussed on investing in the biotechnology and biopharmaceutical sectors, is pleased to announce its interim results for the six month period ending 31 December 2013.
Financial Highlights
Hot Features
Premium
As at 31 December 2013
Profit GBP1,787,086
Earnings per share 5.28 pence
Total assets GBP5,798,952
For further information, please contact:-
Port Erin Biopharma Investments Limited Denham Eke (+44) 1624 639396 Beaumont Cornish Roland Cornish / Felicity Geidt +44 (0) 207 628 3396 Peterhouse Corporate Finance Limited John Levinson +44 (0) 20 7469 0930
Chairman's statement
Introduction
I have great pleasure in presenting the Interim Results for the period ending 31 December 2013.
The Company not only recorded a net profit of GBP1.8 million for the six months, but also following the General Meeting of Shareholders on 11 November 2013, we amended our investing policy to allow for an in specie transfer of cash and assets to acquire 324,174 shares in the Magna Biopharma Investment Fund ("MBIF") at EUR10 per share which was completed on 6 December 2013. The latter followed a strategic review to eliminate the significant discount to Net Asset Value implicit in the Company's share price.
MBIF, as a UCITS fund, is a distinctive new investment proposition, providing exposure to technological innovation but with an attractive income. The investment advisors, including myself, have a proven track record in the Biopharma sector. The advantages of this acquisition to the Company include daily dealing of the fund with no discount to Net Asset Value and a performance fee charged on a relative basis to the MSCI World Health Care Net EUR Index, rather than the absolute basis charged before.
As set out in the circular, at the end of a 12 month lock-in period, the Directors intend to put further proposals to return value to shareholders, either by transferring the Fund's shares as a dividend distribution, share buy-back or other de-merger of assets, in order to realise value for shareholders based on the then proportional Net Asset Value of MBIF shares. By transferring the majority of the investment portfolio in this way, the Company will be able to distribute or sell the MBIF shares at the end of the lock-in period at a price based on the MBIF's Net Asset Value and thereby procure a better return to all shareholders.
Financial Review
During the period, our investment income including dividends, net realised gains on sales, and net unrealised gains was GBP2,340,447 (2012: GBP72,881). Operating expenses, including the performance fee and the professional fees in connection with the in specie purchase of the Magna Biopharma Income shares, were GBP553,384 (2012: GBP68,804), resulting in profit for the period of GBP1,787,086 (2012: GBP9,866).
Thus the basic and diluted earnings per share were 5.28 pence (2012: 0.03 pence).
Our invested assets at fair value were GBP4,991,105 (2012: GBP3,031,135), cash and equivalents were GBP802,741 (2012: GBP101,241). Adding receivables of GBP5,106 (2012: GBP9,035), our total assets stood at GBP5,798,952 (2012: GBP3,141,411).
Our share premium increased to GBP2,759,551 (2012: GBP2,699,013) and our retained earnings increased to GBP2,627,452 (2012: GBP435,075).
Thus the net asset value per share at 31 December 2013 was 15.9 pence (2012: 9.5 pence), an increase of 10.5%.
Strategy and Outlook
Since our acquisition, MBIF generated a net euro return of 6.1% in January 2014, the first full month of operation and comfortably ahead of the 2.8% rise seen in its MSCI World Health Care Index benchmark. The latest available figures for February 2014 showed a further positive month with widespread gains led once again by the biotech sector, which comprises 35% of the portfolio. The Fund generated a net euro return of 3.6% over the month, slightly below the 4.5% rise seen in its MSCI World Health Care Index benchmark. Since launch the Fund is up 12.2%, some 3% ahead of its benchmark.
The fund advisors believe that, in the coming year, important positive announcements will be made for the treatment of currently difficult to treat cancers like melanoma and lung cancer, with immunotherapy and its combinations at big pharmaceutical companies. The MBIF portfolio has been positioned to provide investors with exposure to all of these developments, and also to mitigate the extreme volatility that is inherent in the smaller to medium sized companies in the sector.
By acquiring MBIF shares, thus providing a clear exit strategy for shareholders, the Company has well positioned itself to consider other acquisitions in the sector. Your board is currently considering a number of exciting options which show significant promise.
Jim Mellon
Chairman
Statement of comprehensive income
Notes Period Period Year
ended ended ended
31/12/2013 31/12/2012 30/06/2013
(unaudited) (unaudited) (audited)
GBP GBP GBP
Investment Income 3 2,340,447 72,881 588,966
Operating expenses
Directors' fees 2,5 (7,233) (5,000) (12,192)
Performance fee (379,057) - (60,539)
Other costs 4 (93,276) (57,231) (112,428)
Foreign exchange (losses)/gains (73,818) (6,573) 2,662
---------------- ---------------- ----------------
Profit from operating
activities 5 1,787,063 4,077 406,469
Interest received 23 5,789 8,689
---------------- ---------------- ----------------
Profit before taxation 1,787,086 9,866 415,158
Taxation - - -
---------------- ---------------- ----------------
Profit for the period/year 1,787,086 9,866 415,158
Other comprehensive - - -
income
---------------- ---------------- ----------------
Total comprehensive income for the
period/year 1,787,086 9,866 415,158
Basic and diluted earnings 12 5.28 pence 0.03 pence 1.25 pence
per share
The Directors consider that the Company's activities are continuing.
Statement of financial position
Notes 31/12/2013 31/12/2012 30/06/2013
(unaudited) (unaudited) (audited)
GBP GBP GBP
Current assets
Financial assets at
fair value through profit
or loss 7 4,991,105 3,031,135 2,916,930
Trade and other receivables 5,106 9,035 7,797
Cash and cash equivalents 802,741 101,241 707,624
---------------- ---------------- ----------------
Total assets 5,798,952 3,141,411 3,632,351
Equity and liabilities
Capital and reserves
Share capital 6 34 33 34
Share premium 6 2,759,551 2,699,013 2,759,551
Retained earnings 2,627,452 435,074 840,366
---------------- ---------------- ----------------
5,387,037 3,134,120 3,599,951
Current liabilities
Trade and other payables 9 411,915 7,291 32,400
---------------- ---------------- ----------------
Total equity and liabilities 5,798,952 3,141,411 3,632,351
These financial statements were approved by the Board of Directors on 28 March 2014 and were signed on their behalf by:
Denham Eke
Director
Statement of changes in equity
Share Share Retained
Capital Premium Profit Total
Notes GBP GBP GBP GBP
Balance at 01 July
2013 (audited) 34 2,759,551 840,366 3,599,951
Total comprehensive
income for the period - - 1,787,086 1,787,086
Shares issued 6 - - - -
_________ _________ _________ _________
Balance at 31 December
2013 (unaudited) 34 2,759,551 2,627,452 5,387,037
Share Share Retained
Capital Premium Profit Total
Notes GBP GBP GBP GBP
Balance at 01 July
2012 (audited) 33 2,699,013 425,208 3,124,254
Total comprehensive
income for the period - - 9,866 9,866
Shares issued 6 - - - -
_________ _________ _________ _________
Balance at 31 December
2012 (unaudited) 33 2,699,013 435,074 3,134,120
Statement of cash flows
Notes
Period Period Year
ended ended ended
31/12/ 31/12/ 30/06/2013
2013 2012
(unaudited) (unaudited) (audited)
GBP GBP GBP
Cash flows from operating activities
Profit for the period/year 1,787,086 9,866 415,158
Adjusted for:
Interest received (23) (5,789) (8,689)
Realised and unrealised gains 3 (2,338,021) (66,341) (572,667)
Services settled by way of
issue of shares - - 60,539
-------------- -------------- --------------
Operating loss before changes
in working capital (550,958) (62,264) (105,659)
Decrease in receivables 2,691 545 1,783
Increase/(decrease) in payables 379,515 (24,610) 500
-------------- -------------- --------------
Net cash outflow from operating
activities (168,752) (86,329) (103,376)
-------------- -------------- --------------
Cash flows from investing activities
Purchase of investments (3,395,510) (532,831) (1,720,400)
Proceeds from sale of investments 3,659,356 483,004 2,285,320
Interest received 23 6 8,689
-------------- -------------- --------------
263,869 (49,821) 573,609
-------------- -------------- --------------
(Decrease)/increase in cash
and cash equivalents 95,117 (136,150) 470,233
Cash and cash equivalents at
beginning of period/year 707,624 237,391 237,391
-------------- -------------- --------------
Cash and cash equivalents at
the end of period/year 802,741 101,241 707,624
Notes to the financial statements
1 Accounting policies
Port Erin Biopharma Investments Limited is a Company domiciled in the Isle of Man. The Company's strategy is to create value for Shareholders through investing in companies that have the potential to generate substantial revenues through the development of biopharmaceutical drugs.
The principal accounting policies are set out below.
a) Statement of compliance
These condensed interim financial statements have been prepared in accordance with IAS34 Interim Financial Reporting and do not include all of the information required for full annual financial statements..
The financial statements were approved by the Board of Directors on 28 March 2014.
b) Basis of preparation
Use of estimates and judgment
The preparation of financial statements in conformity with IFRS requires management to make judgements, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, income and expenses. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgements about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.
The estimates and underlying assumptions are reviewed on an on-going basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision only affects that period or in the period of the revision and future periods if the revision affects both current and future periods.
Going concern
The financial statements have been prepared on a going concern basis, taking into consideration the level of cash and cash equivalents and short term investments held by the Company. The Directors have a reasonable expectation that the Company will have adequate resources for its continuing existence and projected activities for the foreseeable future, and for these reasons, continue to adopt the going concern basis in preparing the financial statements for the period ended 31 December 2013.
Functional and presentation currency
These financial statements are presented in Pound Sterling which is the Company's functional currency and rounded to the nearest Pound.
c) Significant accounting policies
The accounting policies adopted by the Company in the preparation of these condensed interim financial statements are the same as those applied by the Company in its financial statements as at and for the year ended 30 June 2013. There were no new accounting policies adopted during the period.
The audited financial statements of the Company as at and for the year ended 30 June 2013 are available at the Company's website below:
http://www.porterinbiopharma.com/financial_reports.php
2 Directors' fees
The fees of Directors who served during the period to 31 December 2013 were as follows:
31/12/13 31/12/12 30/06/2013
(unaudited) (unaudited) (audited)
GBP GBP GBP
James Mellon - - -
Nicholas James Woolard - 5,000 10,000
Denham Eke - - -
Alexander Anderson Stuart Whamond 7,233 - 2,192
-------------- -------------- --------------
7,233 5,000 12,192
On 6 May 2011, Shellbay Investments Limited entered into a letter of appointment with the Company to provide the services of James Mellon as Non-Executive Chairman of the Company. Remuneration under the letter of appointment shall be payable to Shellbay Investments Limited and shall be satisfied by the issue of such number of Ordinary Shares equivalent to 15.0 per cent. of any increase in the Net Asset Value of the Company over each quarterly period. There are no provisions providing for any benefit to Shellbay Investments Limited or James Mellon on the termination of the engagement. The Director of Shellbay Investments Limited has agreed to waive any share-based payments until the Net Asset Value of each share exceeds 10.00 pence.
On the 6 December 2013, the Company agreed that the Management Fee of GBP353,041 for the period to 30 September 2013 shall be settled by the transfer of sufficient Fund Shares from the Company to Shellbay (each with an implied price equal to the Subscription Price) in full and final settlement of the September 2013 Management Fee. Shellbay agreed that the current Management Agreement shall be amended so that no further fees relating to the Magna Biopharma Income Fund (MBIF) Shares under the current Management Agreement shall be due and the current "high watermark" rebased to reflect the value of the other assets remaining in the Company following the Subscription. Any future fees due to Shellbay will be settled by the transfer of MBIF Shares at the offer price prevailing on the quarterly valuation date
On 6 May 2011 Nicholas James Woolard entered into a letter of appointment with the Company to provide services as a Non-Executive Director of the Company. The letter of appointment was for an initial period of twelve months, from 16 May 2011, and may be terminated on not less than three months' notice given by either party to the other at any time. The letter of appointment contains provisions for early termination, inter alia, in the event of a breach by Nicholas James Woolard. Remuneration under the letter of appointment was for an annual fee of GBP10,000 payable on a quarterly basis. There are no provisions providing for any benefit to Nicholas James Woolard on the termination of the engagement. Nicholas Woolard resigned from his position on 12 April 2013.
Denham Eke, appointed a Director on 30 May 2012, currently receives no remuneration for providing his services.
As at 6 December 2013, the value of non-MBIF assets held by the Company was GBP2,052,035. As at the 31 December 2013, the value of non-MBIF assets had increased to GBP2,225,475. Thus, under the revised Shellbay Letter of Appointment, the increase in Net Asset Value of GBP173,440.15 will be settled by a performance fee of 15%, which is GBP26,016.
At present, there are no other fees due by the Company in respect of investment management services.
3 Investment income
31/12/2013 31/12/2012 30/06/2013
(unaudited) (unaudited) (audited)
GBP GBP GBP
Dividend income 2,426 6,541 16,299
Net realised gains on sale of
investments 966,330 50,529 769,484
Net unrealised gains on investments 1,371,691 15,812 (196,817)
-------------- -------------- --------------
2,340,447 72,881 588,966
4 Other costs
31/12/2013 31/12/2012 30/06/2013
(unaudited) (unaudited) (audited)
GBP GBP GBP
Auditors' remuneration for the
current period/year 8,625 7,200 14,904
Bank charges 209 119 415
Insurance 3,193 3,176 6,283
Marketing 3,575 72 72
Professional fees 77,299 46,664 86,555
Sundry expenses 375 - 4,199
-------------- -------------- --------------
93,276 57,231 112,428
The Company has no employees other than the Directors.
5 Profit from operating activities
Profit from operating activities is stated after charging:
31/12/2013 31/12/2012 30/06/2013
(unaudited) (unaudited) (audited)
GBP GBP GBP
Auditors' fees 8,625 7,200 14,400
Directors' fees 7,233 5,000 10,000
-------------- -------------- --------------
15,858 12,200 24,400
6 Share capital and share premium
Each share in the Company confers upon the shareholder:
-- the right to one vote at a meeting of the shareholders or on any resolution of shareholders; -- the right to an equal share in any dividend paid by the Company, and
-- the right to an equal share in the distribution of the surplus assets of the Company on its liquidation
The Company may by resolution of Directors redeem, purchase or otherwise acquire all or any of the shares in the Company subject to regulations set out in the Company's Articles of Association.
31/12/2013 31/12/2012 30/06/2013
(unaudited) (unaudited) (audited
GBP GBP GBP
Authorised
2,000,000,000 Ordinary shares
of GBP0.000001 2,000 2,000 2,000
No. of Share Share
Shares Capital Premium
GBP GBP
Balance at 01 July 2012/
31 December 2013 33,000,000 33 2,699,013
Shares issued in settlement
of services 864,836 1 60,538
-------------- -------------- --------------
Balance at 30 June 2013/
31 December 2013 33,864,836 34 2,759,551
On 9 April 2013 the Company issued 864,836 ordinary shares at a price of GBP0.07 each resulting in share premium of GBP60,538. The shares were issued to Shellbay Investments Limited in settlement of services provided to the Company (see note 2)
Capital management
The Company manages its capital to maximise the return to shareholders through the optimisation of equity. The capital structure of the Company as at 31 December 2013 consists of equity attributable to equity holders of the Company, comprising issued capital, reserves and retained earnings as disclosed.
The Company manages its capital structure and makes adjustments to it in the light of economic conditions and the strategy approved by shareholders. To maintain or adjust the capital structure, the Company may make dividend payment to shareholders, return capital to shareholders or issue new shares and release the share premium account. No changes were made in the objectives, policies or processes during the period under review.
Dividends
No dividends were declared or proposed by the Directors during the period (31 December 2012: Nil).
7 Financial assets at fair value through profit or loss
31/12/2013 31/12/2012 30/06/2013
(unaudited) (unaudited) (audited)
GBP GBP GBP
Quoted 4,671,135 2,709,427 2,667,817
Unquoted 319,970 321,708 249,113
-------------- -------------- --------------
4,991,105 3,031,135 2,916,930
Equities 4,901,454 3,007,987 2,900,677
Warrants 89,651 23,148 16,253
-------------- -------------- --------------
4,991,105 3,031,135 2,916,930
8 Financial instruments
Financial Risk Management
All aspects of the Company's financial risk management objectives and policies are consistent with those disclosed in the financial statements as at and for the year ended 30 June 2013.
9 Trade and other payables
31/12/2013 31/12/2012 30/06/2013
(unaudited) (unaudited) (audited)
GBP GBP GBP
Provision for audit fee 7,500 7,200 18,000
Shellbay Investments Limited 379,057 - -
Other 25,358 90 14,400
-------------- -------------- --------------
411,915 7,290 32,400
10 Share warrants
At the date of admission to AIM, the Company issued 30,000,000 non-transferable warrants, entitling the holder to subscribe for one new ordinary share for every placing share, and which will not be admitted to trading on AIM. The warrants were exercisable for 12.5 pence at any time within two years of the date of issue. The warrant exercise was either at the option of the holder or at the option of the Company, in the event that the closing price of the ordinary shares was more than 20 pence for five consecutive trading days. In considering the share subscription price, the lack of historic share price performance data, and the price and conditions attaching to exercise, the Directors deemed that the warrants had no separate value from the shares issued on the Company's admission to AIM.
All warrants lapsed on 15 September 2013 and there were thus no warrants in issue at the year-end.
11 Related party transaction
Under an agreement dated 1 December 2011, Burnbrae Limited, a Company related to both James Mellon and Denham Eke, provide certain services, principally accounting and administration, to the Company. This agreement may be terminated by either party on three months' notice. The Company incurred a total cost of GBP18,000 (31 December 2012: GBP18,000) during the period under this agreement of which GBP Nil was outstanding as at the period end (31 December 2012: GBP Nil).
12 Basic and diluted earnings per share
The calculation of basic earnings per share of the Company is based on the profit for the period of GBP1,787,086 (31 December 2012: GBP9,866) and the weighted average number of shares of 33,864,836 (31 December 2012: 33,000,000) in issue during the period.
Diluted earnings per share are calculated by adjusting the weighted average number of ordinary shares outstanding to assume conversion of all dilutive potential ordinary shares such as warrants and options. There is no dilutive effect at 31 December 2013 because the warrants have lapsed.
13 Commitments and contingent liabilities
There are no known commitments or contingent liabilities as at the period end.
14 Events after the reporting date
There have been no material events since the reporting date that require disclosure in the interim financial statements.
This information is provided by RNS
The company news service from the London Stock Exchange
END
IR PGUGCWUPCGMR
1 Year Agronomics Chart |
1 Month Agronomics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
